Signaturefd LLC Increases Position in Genmab A/S (NASDAQ:GMAB)

Signaturefd LLC increased its stake in Genmab A/S (NASDAQ:GMAB) by 163.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,790 shares of the company’s stock after acquiring an additional 12,890 shares during the period. Signaturefd LLC’s holdings in Genmab A/S were worth $434,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Two Sigma Advisers LP grew its position in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after acquiring an additional 280,900 shares in the last quarter. FMR LLC boosted its position in Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after buying an additional 33,076 shares during the period. Natixis Advisors LLC boosted its position in Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after buying an additional 47,437 shares during the period. ABC Arbitrage SA purchased a new stake in Genmab A/S during the fourth quarter valued at about $3,692,000. Finally, AIMZ Investment Advisors LLC purchased a new stake in Genmab A/S during the fourth quarter valued at about $3,525,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GMAB shares. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, Truist Financial dropped their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Price Performance

GMAB stock opened at $19.84 on Friday. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.02. The company has a market cap of $13.13 billion, a P/E ratio of 11.40, a PEG ratio of 2.65 and a beta of 0.98. The firm has a 50-day moving average of $21.09 and a 200 day moving average of $22.25.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.